

Additional file 1. ImmunoCAP analyses of AIT patients' sera.

Patients	Bet v 1-specific IgE			Bet v 2-specific IgE			Bet v 4-specific IgE			Total IgE			Bet v 1-specific IgG4		
	[kUA/l]			[kUA/l]			[kUA/l]			[kU/l]			[mgA/l]		
	T0	T1	T2	T0	T1	T2	T0	T1	T2	T0	T1	T2	T0	T1	T2
P1	40.2	42.7	19.8	<0.1	<0.1	<0.1	<0.01	<0.01	<0.01	90.5	80.3	49.9	0.3	0.6	4.3
P2	4.4	5.8	4.8	<0.01	<0.1	<0.1	<0.01	<0.01	<0.01	23.2	28.7	22.0	0.2	1.9	3.3
P3	26.3	53.3	38.0	<0.1	<0.1	<0.1	<0.01	<0.01	<0.01	188.0	203.0	156.0	0.7	3.0	3.5
P4	51.1	159.0	81.3	<0.1	0.1	0.17	<0.01	<0.01	<0.01	292.0	463.0	488.0	<0.1	2.9	4.3
P5	10.3	17.5	10.0	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	37.1	51.9	40.5	1.3	5.7	4.6

P1–5, AIT patients; T0, before AIT; T1, two weeks after reaching the maintenance dose; T2, one year after starting AIT